In a reader survey, researchers and core lab staff share how they think cores are doing.
GreenLight Biosciences is using a proprietary cell-free RNA production technology to develop RNA-based products for the agricultural market.
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Researchers are working on RNA inference-based pesticides for crops, according to Digital Trends.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.
Researchers from the Broad Institute and Novartis used RNA interference to generate catalogs of genes that cancer cells rely on to grow and survive.
The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.
Researchers described the development and testing of layered double hydroxide nanosheets as carriers for RNAi molecules in agriculture.
An Australian team has developed a method to spray double-stranded RNA on plants to make them resistant to pests, Technology Review reports.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.